Teva and Sanofi report Duvakitug maintained efficacy through 44 weeks in ulcerative colitis and Crohn's disease

Teva Pharmaceuticals and Sanofi reported that Duvakitug maintained efficacy through 44 weeks in ulcerative colitis and Crohn's disease.

Detected & updated continuously · Source: Nebula